Zinacef powder for solution for injection

Country: Հայաստան

language: անգլերեն

source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

active_ingredient:

cefuroxime (cefuroxime sodium)

MAH:

GlaxoSmithKline Manufacturing SpA

ATC_code:

J01DC02

INN:

cefuroxime (cefuroxime sodium)

dosage:

750mg

pharmaceutical_form:

powder for solution for injection

units_in_package:

glass vial

prescription_type:

Prescription

authorization_status:

Registered

authorization_date:

2019-12-26

SPC

SUMMARY OF PRODUCT CHARACTERISTICS
_ZINACEF_™
CEFUROXIME SODIUM
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ZINACEF _Injection contains 250 mg, 750 mg, 1 g and 1.5 g of
cefuroxime (as cefuroxime
sodium).
_ZINACEF MONOVIAL™ _contains 750 mg and 1.5 g of cefuroxime (as
cefuroxime sodium).
PHARMACEUTICAL FORM
Powder for solution for injection (Injection) Powder
for solutuon for infusion (_MONOVIAL_)
CLINICAL PARTICULARS
INDICATIONS
_ZINACEF _is a bactericidal cephalosporin antibiotic which is
resistant to most
beta-lactamases and is active against a wide range of Gram-positive
and Gram-negative
organisms.
It is indicated for the treatment of infections before the infecting
organism has been identified
or when caused by sensitive bacteria. Susceptibility to _ZINACEF _will
vary with geography and
time and local susceptibility data should be consulted where available
(_see Pharmacological _
_properties, Pharmacodynamics_).
Indications include:

respiratory tract infections for example, acute and chronic
bronchitis, infected
bronchiectasis, bacterial pneumonia, lung abscess and post-operative
chest infections

ear, nose and throat infections for example, sinusitis, tonsillitis,
pharyngitis and otitis
media

urinary tract infections for example, acute and chronic
pyelonephritis, cystitis and
asymptomatic bacteriuria

soft-tissue infections for example, cellulitis, erysipelas and wound
infections

bone and joint infections for example, osteomyelitis and septic
arthritis

obstetric and gynaecological infections, pelvic inflammatory diseases

gonorrhoea particularly when penicillin is unsuitable

other infections including septicaemia, meningitis and peritonitis

prophylaxis against infection in abdominal, pelvic, orthopaedic,
cardiac, pulmonary,
oesophageal and vascular surgery where there is increased risk from
infection.
Usually _ZINACEF _will be effective alone, but when appropriate it may
be used in combination
with an aminoglycoside antibiotic, or in conjunction with
metronidazole (orally